Paid Clinical Trials and Focus Groups by Category |
|
|
|
Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: sunitinib malate
Sponsor: Wales Cancer Trials Unit
Recruiting - verified March 2010
Condition: Bladder Cancer
Intervention: Other: Neo-Urinary Conduit
Sponsor: Tengion
Recruiting - verified March 2010
Conditions: Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Gastrointestinal Complications; Long-term Effects Secondary to Cancer Therapy in Adults; Ovarian Cancer; Prostate Cancer; Radiation Toxicity; Sarcoma; Testicular Germ Cell Tumor; Vaginal Cancer
Interventions: Other: questionnaire administration; Procedure: gastrointestinal complications management/prevention; Procedure: quality-of-life assessment
Sponsor: Royal Marsden NHS Foundation Trust
Recruiting - verified March 2010
Condition: Bladder Cancer
Interventions: Drug: Bacille Calmette-Guerin; Drug: uracil-tegafur
Sponsor: Urological Oncology Council of Northern Tokyo
Recruiting - verified March 2010
Condition: Bladder Cancer
Interventions: Procedure: open radical cystectomy; Procedure: robotic-assisted radical cystectomy
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010
Conditions: Bladder Cancer; Skin Cancers
Intervention:
Sponsors: Stanford University; National Institutes of Health (NIH); Providence Foundation
Recruiting - verified February 2010
Conditions: Depressive Disorder; Cancer
Interventions: Drug: Regular bupropion use; Drug: Regular SSRI (Selective serotonin reuptake inhibitors) use; Drug: Regular use of any other antidepressant; Drug: Regular TCA (Tricyclic antidepressants) use
Sponsor: GlaxoSmithKline
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Intervention: Device: CONTINUUM™
Sponsor: American Medical Systems
Recruiting - verified March 2010
Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Drug: pazopanib hydrochloride; Radiation: fludeoxyglucose F 18
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting - verified March 2010
Conditions: Urothelial Cancer; Bladder Cancer
Intervention: Drug: ABI-007 (Abraxane®)
Sponsors: University of Michigan Cancer Center; Abraxis BioScience Inc.
Recruiting - verified March 2010
Condition: Bladder Cancer
Interventions: Drug: Mitomycin C (MMC); Biological: TheracysR Bacillus Calmette-Guerin (BCG)
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Condition: Bladder Neoplasms
Intervention: Radiation: Radiation boost
Sponsors: University of Aarhus; Aarhus University Hospital
Recruiting - verified February 2010
Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Bladder Cancer
Intervention: Other: Using Cone beam CT in patients with Bladder Cancer
Sponsor: University Health Network, Toronto
Recruiting - verified February 2010
Condition: Cancer
Interventions: Other: immunological diagnostic method; Other: physiologic testing
Sponsors: Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified June 2009
Condition: Bladder Cancer
Interventions: Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsor: Institute of Cancer Research, United Kingdom
Active, not recruiting - verified March 2009
Condition: Prostate Cancer
Intervention: Behavioral: QOL Questionnaire
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Conditions: Bladder Cancer; Urinary Bladder
Intervention: Drug: Gemcitabine, Cisplatin, and Sunitinib
Sponsors: Memorial Sloan-Kettering Cancer Center; Pfizer
Recruiting - verified March 2010
Condition: Bladder Cancer
Intervention:
Sponsor: University of Colorado, Denver
Active, not recruiting - verified January 2009
Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Urinary Incontinence
Interventions: Drug: Non-Surgical Intervention; Procedure: Surgical
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Alabama at Birmingham; University of California, San Diego; University of Maryland; University of Pittsburgh; University of Texas; University of Utah; Beaumont Hospital; Loyola University; New England Research Institutes
Terminated - verified March 2010
Conditions: Bladder Cancer; Brain and Central Nervous System Tumors; Esophageal Cancer; Intraocular Melanoma; Kidney Cancer; Lymphoma; Melanoma (Skin); Pancreatic Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration
Sponsor: Cancer Research UK
Recruiting - verified September 2008
Conditions: Non-Small Cell Lung; Breast Cancer; Melanoma; Upper GI Tract Carcinoma; Colon Carcinoma; Renal Cell Carcinoma; Bladder Carcinoma; Prostate Cancer
Interventions: Biological: V935; Biological: V934 EP (3 doses) and V935 (2 doses); Biological: V934 EP (5 doses) + V935 (2 doses); Biological: V934 DNA EP (3 doses)
Sponsor: Merck
Active, not recruiting - verified February 2010
Condition: Transitional Cell Carcinoma of the Bladder
Interventions: Drug: Dasatinib; Procedure: Radical Cystectomy
Sponsors: Hoosier Oncology Group; Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Radiation: Conventional Fractionated Intensity Modulated Radiotherapy; Radiation: Hypofractionated Intensity Modulated Radiotherapy
Sponsor: M.D. Anderson Cancer Center
Active, not recruiting - verified February 2010
Condition: Urinary Bladder Neoplasms
Interventions: Drug: larotaxel (XRP9881); Drug: gemcitabine; Drug: cisplatin
Sponsor: Sanofi-Aventis
Active, not recruiting - verified February 2010
Conditions: Advanced Non-Small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Bladder Cancer
Interventions: Other: Computed Tomography Urography (CTU); Other: Intravenous Urography (IVU)
Sponsors: M.D. Anderson Cancer Center; GE Healthcare
Recruiting - verified March 2010
Conditions: Myeloproliferative Disorder; Urothelial Carcinoma; Cancer
Intervention: Drug: Bevacizumab, Carboplatin, Gemcitabine
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Condition: Bladder Cancer
Interventions: Procedure: quality-of-life assessment; Procedure: questionnaire administration
Sponsor: University of Birmingham
Recruiting - verified February 2010
Condition: Cancer
Interventions: Drug: fentanyl sublingual spray; Other: questionnaire administration
Sponsor: Insys Therapeutics Inc
Recruiting - verified October 2008
Conditions: Uterine Cancer; Cervical Cancer; Endometrial Cancer
Interventions: Radiation: Intensity Modulated Radiotherapy (IMRT); Procedure: CT Scan
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Condition: Neoplasms
Interventions: Drug: OGX-427; Drug: Docetaxel
Sponsor: OncoGenex Technologies
Recruiting - verified February 2010
Conditions: Solid Tumor; Urethral Cancer
Interventions: Drug: Bortezomib; Drug: Gemcitabine; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Conditions: Bladder Cancer; Breast Cancer; Kidney Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: custirsen sodium; Drug: docetaxel; Other: pharmacological study
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Condition: Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Drug: eribulin mesylate; Other: pharmacological study
Sponsors: California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Bladder Cancer
Interventions: Biological: BCG vaccine; Drug: gefitinib; Procedure: quality-of-life assessment
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Condition: Bladder Cancer
Interventions: Biological: trastuzumab; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Bladder Cancer
Intervention:
Sponsors: Maastricht Radiation Oncology; Maastricht University Medical Center
Withdrawn - verified March 2010
Condition: Urinary Incontinence
Interventions: Behavioral: Behavioral Therapy; Device: Pelvic Floor Electrical Stimulation; Behavioral: Biofeedback; Behavioral: Self Monitoring with Bladder Diaries
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified March 2010
Conditions: Lung Cancer; Breast Cancer; Bladder Cancer; Ovarian Cancer; Pancreatic Cancer
Interventions: Drug: AMG 706; Biological: Panitumumab; Drug: Gemcitabine/Cisplatin
Sponsor: Amgen
Terminated - verified February 2010
Conditions: Transitional Cell Carcinoma; Bladder Neoplasms; Kidney Neoplasms; Ureter Neoplasms; Bladder Cancer; Neoplasm, Bladder
Intervention: Drug: vinflunine
Sponsors: Bristol-Myers Squibb; Pierre Fabre Medicament
Completed - verified August 2008
Condition: Cancer
Interventions: Drug: docetaxel; Drug: thalidomide
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010
Condition: Cancer
Intervention: Drug: entinostat
Sponsor: National Cancer Institute (NCI)
Completed - verified February 2007
All Categories ... by Medical Condition » ... Cancers » ... Bladder Cancer 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
